Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism : The RIETECAT study
Trujillo-Santos, Javier (Hospital General Universitario Santa Lucía (Cartagena, Múrcia))
Farge-Bancel, Dominique (Université de Paris)
Pedrajas, José María (Hospital Clínico San Carlos (Madrid))
Gómez-Cuervo, Covadonga (Hospital 12 de Octubre (Madrid))
Ballaz, Aitor (Hospital de Galdakao (Usansolo, Biscaia))
Braester, Andrei (Bar-Ilan University)
Mahé, Isabelle (Hôpital Louis Mourier)
Villalobos, Aurora (Hospital Regional Universitario de Málaga)
Porras, José Antonio (Hospital Universitari Joan XXIII de Tarragona)
Monreal, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. The objective of the RIETECAT study was to compare the long-term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active cancer. We used the data from the multicenter, multinational RIETE registry to compare the rates of VTE recurrences, major bleeding, or death over 6 months in patients with active cancer and acute VTE using full doses of enoxaparin versus dalteparin or tinzaparin, and a multivariable Cox proportional hazard model was used to analyze the primary end point. From January 2009 to June 2018, 4451 patients with active cancer received full doses of the study drugs: enoxaparin, 3526 patients; and dalteparin or tinzaparin, 925 (754 + 171) patients. There was limited difference in VTE recurrences (2. 0% vs 2. 5%) and mortality rate (19% vs 17%) between the enoxaparin and dalteparin or tinzaparin subgroups. However, there was a slight numerical increase in major bleeding (3. 1% vs 1. 9%). Propensity score matching confirmed that there were no differences in the risk for VTE recurrences (adjusted hazard ratio [aHR], 0. 81; 95% confidence interval [CI], 0. 48-1. 38), major bleeding (aHR, 1. 40; 95% CI, 0. 80-2. 46), or death (aHR, 1. 07; 95% CI, 0. 88-1. 30) between subgroups. In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Cancer ; Cohort ; Dalteparin ; Enoxaparin ; LMWH ; Recurrences ; Tinzaparin ; Venous thromboembolism
Published in:	Research and Practice in Thrombosis and Haemostasis, Vol. 6 (june 2022) , ISSN 2475-0379

DOI: 10.1002/rth2.12736
PMID: 35664535

10 p, 839.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles